DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not on insulin. Management highlighted progress in commercial coverage for this group, with expanded access helping to offset a slower pace of new patient starts in the U.S. While the company posted results above Wall Street’s expectations on both revenue and profit, the market responded negatively, reflecting concerns about U.S. market growth moderation. CEO Jake Leach acknowledged that while demand remains strong, “there is still a long runway to go” given only about one-third of covered lives are currently using continuous glucose monitoring (CGM) technology.

Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From DexCom’s Q1 Earnings Call

• David Roman (Goldman Sachs) questioned U.S. market growth amid slowing coverage expansion. CEO Jake Leach responded that only 30% of eligible lives use CGM, and coverage expansion plus targeted sales efforts should support continued growth.

• Travis Steed (Bank of America) asked about the impact of the G7 15-day product on new patient starts and margins. Leach credited the new sensor’s algorithm and wear time for driving adoption, while CFO Jereme Sylvain explained that input cost inflation is the main reason gross margin guidance remains unchanged.

• Gursimran Kaur (Wells Fargo) inquired about the potential of the type 2 non-insulin RCT to unlock the next phase of growth. Leach said the ADA readout will be the first full release and emphasized durable growth potential with expanded coverage.

• Robbie Marcus (JPMorgan) pressed on whether the pace of new patient starts is sufficient to maintain growth. Sylvain clarified that global new patient starts set a record and that ongoing coverage unlocks and product launches should continue to drive growth.

• Matthew Taylor (Jefferies) asked if CMS may grant coverage prior to RCT publication. Leach responded that while timing is uncertain, the evidence base is strong and coverage could occur sooner than expected.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will be monitoring (1) the results and payer impact of the type 2 non-insulin RCT at the ADA Scientific Sessions, (2) the pace and scale of G7 15-day sensor adoption in both U.S. and international markets, and (3) additional commercial and Medicare coverage expansions for type 2 diabetes patients. Execution on digital ecosystem enhancements and progress in international tenders will also be critical to DexCom’s growth trajectory.

DexCom currently trades at $60.65, up from $59.55 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.